SCHEMBL7124017

SCHEMBL7124017

CC(C)Cc1c(O)c2cc(F)ccc2[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.46
ALDH1A1 P00352 5/20 0.46
GSK3B P49841 1/20 0.45
HSD17B10 Q99714 4/20 0.43
HPGD P15428 3/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
DAO P14920 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
FEN1 P39748 1/20 0.41
NPC1 O15118 1/20 0.41
USP2 O75604 1/20 0.41
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PGR P06401 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7122354 0.84 KDM5A (0.54) KDM4EALDH1A1GSK3BHSD17B10HPGD
SCHEMBL7120211 0.83 ALDH1A1 (0.62) KDM4EALDH1A1GSK3BHSD17B10HPGD
SCHEMBL7121392 0.82 KDM4E (0.65) KDM4EALDH1A1GSK3BHSD17B10HPGD
SCHEMBL7114921 0.78 DAO (0.46) KDM4EALDH1A1GSK3BKEAP1NFE2L2
SCHEMBL7114063 0.77 GSK3B (0.47) KDM4EALDH1A1GSK3BKEAP1NFE2L2
SCHEMBL7552688 0.76 ALDH1A1 (0.51) KDM4EALDH1A1GSK3BHSD17B10HPGD
SCHEMBL7123791 0.76 KEAP1 (0.54) KDM4EALDH1A1GSK3BKEAP1NFE2L2
SCHEMBL3422670 0.76 KDM4E (0.53) KDM4EALDH1A1HPGDKEAP1NFE2L2
SCHEMBL23259264 0.75 KIF11 (0.45) KDM4EALDH1A1HSD17B10KEAP1NFE2L2
SCHEMBL6519610 0.72 GSK3B (0.56) KDM4EALDH1A1GSK3BKEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 KDM4E 3240/4885ALDH1A1 1742/4885GSK3B 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.